Minimax and admissible adaptive two-stage designs in phase II clinical trials

Table 1 The proposed adaptive minimax design for the urothelial cancer trial with the neoadjuvant therapy with (α,β,π_u,π_a)=(0.1,0.2,0.35,0.5)

S	n₂(S)	n(S)	r(S)
Minimax-EF design
≤11	0	32	0
12	17	49	21
13	17	49	21
14	17	49	21
15	17	49	21
16	17	49	21
≥17	0	32	0
Minimax adaptive design
≤9	0	28	0
10	21	49	21
11	21	49	21
12	21	49	21
13	21	49	21
14	19	47	20
15	18	46	20
≥16	0	28	0

ISSN: 1471-2288